Novogen Ltd. (NASDAQ:NVGN)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued on Tuesday.
Novogen (NASDAQ:NVGN) remained flat at $2.00 on Tuesday. 24,540 shares of the stock traded hands. Novogen has a one year low of $1.72 and a one year high of $3.09. The stock’s market cap is $34.38 million. The firm’s 50-day moving average price is $1.99 and its 200-day moving average price is $2.08.
Novogen Company Profile
Novogen Limited (Novogen) is a drug discovery company. The Company is primarily engaged in pharmaceutical research and development. The Company’s operations include CanTx Inc, its United States-based joint venture company with Yale University. Novogen has two drug technology platforms (the superbenzopyrans (SBPs) and anti-tropomyosins (ATMs)) yielding drug candidates that have application across a range of degenerative diseases.
Receive News & Ratings for Novogen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novogen Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.